Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Chemo-immunotherapy for TNBC

Serafin Morales • 12 May 2020
ESMO Breast 2020
Breast Cancer Checkpoint Inhibitors

Serafin Morales, PhD, of the University Hospital Arnau de Vilanova, Lleida, Spain, discusses the use of both immunotherapy and chemotherapy in the treatment of triple-negative breast cancer (TNBC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Serafin Morales

2:29
Using genomic techniques to guide personalized medicine in breast cancer
Serafin Morales • 19 May 2020
4:37
Latest advances in breast cancer research
Serafin Morales • 12 May 2020
2:17
Loss of HER2 after neoadjuvant treatment of HER2+ early BC
Serafin Morales • 13 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals